Search
Results: 3
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Izanne Roos, Emmanuelle Leray, Federico Frascoli, Romain Casey, J William L Brown, Dana Horakova, Eva K Havrdova, Maria Trojano, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marco Onofrj, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Grammond, Patrizia Sola, Diana Ferraro, Serkan Ozakbas, Roberto Bergamaschi, Maria José Sá, Elisabetta Cartechini, Cavit Boz, Franco Granella, Raymond Hupperts, Murat Terzi, Jeannette Lechner-Scott, Daniele Spitaleri, Vincent Van Pesch, Aysun Soysal, Javier Olascoaga, Julie Prevost, Eduardo Aguera-Morales, Mark Slee, Tunde Csepany, Recai Turkoglu, Youssef Sidhom, Riadh Gouider, Bart Van Wijmeersch, Pamela McCombe, Richard Macdonell, Alasdair Coles, Charles B Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik, MSBase, OFSEP investigators
Sep 24, 2020
In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity. Whilst immunomodulatory therapies reduce disease activity, the time required to attain maximal effect is unclear. In this study we...
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
J William L Brown, Alasdair Coles, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Maria Trojano, Alessandra Lugaresi, Roberto Bergamaschi, Pierre Grammond, Raed Alroughani, Raymond Hupperts, Pamela McCombe, Vincent Van Pesch, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi, Jeannette Lechner-Scott, Schlomo Flechter, Mark Slee, Vahid Shaygannejad, Eugenio Pucci, Franco Granella, Vilija Jokubaitis, Mark Willis, Claire Rice, Neil Scolding, Alastair Wilkins, Owen R Pearson, Tjalf Ziemssen, Michael Hutchinson, Katharine Harding, Joanne Jones, Christopher McGuigan, Helmut Butzkueven, Tomas Kalincik, Neil Robertson, MSBase Study Group
Feb 07, 2019
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, A Wilkins, O Pearson, T Ziemssen, M Hutchinson, C McGuigan, V Jokubaitis, T Spelman, D Horakova, E Havrdova, M Trojano, G Izquierdo, A Lugaresi, A Prat, M Girard, P Duquette, P Grammond, R Alroughani, E Pucci, P Sola, R Hupperts, J Lechner-Scott, M Terzi, V Van Pesch, C Rozsa, F Grand'Maison, C Boz, F Granella, M Slee, D Spitaleri, J Olascoaga, R Bergamaschi, F Verheul, S Vucic, P McCombe, S Hodgkinson, JL Sanchez-Menoyo, R Ampapa, M Simo, T Csepany, C Ramo, E Cristiano, M Barnett, H Butzkueven, A Coles, MSBase Study Group
Mar 28, 2017